Introduction {#s1}
============

Sarcomas are a rare group of solid malignant mesenchymal tumours, which comprise more than 70 histological subtypes. They have considerable heterogeneity with respect to age of onset, anatomic location, tempo of progression and outcome. Approximately 80% of sarcomas originate in soft tissue, the remainder in bone. Sarcomas form a typical example of rare cancers, with an estimated European incidence averaging 4--5 per 100 000 per year.[@R1] Patients with rare cancers have a higher mortality rate than those with common cancers because of delays to accurate diagnosis and subsequent suboptimal or inadequate treatment, fewer developments in novel therapies and reduced opportunities to participate in clinical trials.[@R2]

Early and accurate diagnosis of cancer is important to optimise patient outcomes in terms of local disease control, overall survival and health-related quality of life (HRQoL).[@R3] The absence of a typical and uniform sarcoma presentation, the lack of public awareness, and the limited experience of primary and secondary healthcare professionals with sarcomas can result in a prolonged total interval and late referral to specialist sarcoma centres. The total interval is the time between first symptoms and (preferably histological) diagnosis([figure 1](#F1){ref-type="fig"}).[@R5] To date, the impact of late referrals on sarcoma patient outcomes has been understudied and reports have been contradictory.

![Time intervals in the route from first symptom until start of treatment. Adapted from Olesen *et al* [@R5] 2009. Total interval: from first symptom to diagnosis; patient interval: from the date the patient first noticed a sarcoma-related symptom until the first presentation to a doctor with this symptom; Diagnostic interval: from first presentation to a doctor until diagnosis; primary care interval: from first presentation to a general practitioner until first referral to secondary care (if applicable) or to a specialist sarcoma centre; secondary care interval: from referral to secondary care until referral to tertiary care (a specialist sarcoma centre); tertiary care interval: from referral to a specialist sarcoma centre until the date of (histological) diagnosis.](esmoopen-2019-000592f01){#F1}

To inform interventions that shorten the total interval, better insights are needed into the determinants of each component of the total interval, such as sociodemographic, clinical, psychological and healthcare factors. The aim of this systematic review is to examine the total interval of sarcoma patients by quantifying its length, identifying contributing factors and determine the impact on patients' outcome in terms of mortality and HRQoL.

Material and methods {#s2}
====================

Search strategy {#s2-1}
---------------

We conducted a systematic review according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@R6]

A computerised search of the literature through PubMed (1946--present), MEDLINE (1950--present), EMBASE (1974--present), Web of Science (1945--present) and Cochrane Library was carried out with the help of a librarian of the Radboudumc by two researchers (vs and OH) on 28 February 2019. The search strategy combined terms related to 'sarcoma', 'delayed diagnosis', 'early diagnosis' or 'referral'. The search string is presented in [online supplementary material A](#SP1){ref-type="supplementary-material"}.

10.1136/esmoopen-2019-000592.supp1

Selection criteria {#s2-2}
------------------

Studies were included if they met the following criteria: (1) study participants had a proven diagnosis of sarcoma; (2) the total interval or any of its components as defined in [figure 1](#F1){ref-type="fig"} were available and (3) the full-text paper was available in English. Reviews were excluded because they did not contain original data and single case reports were excluded to limit selection bias.

Definition {#s2-3}
----------

The following definition was used: the total interval, defined as time between first symptoms and (histological) diagnosis, which includes both a patient and diagnostic interval; the latter can be further divided into a primary, secondary and tertiary care interval. The intervals and their associated time points are illustrated in [figure 1](#F1){ref-type="fig"}. This figure was adapted from Olesen *et al* [@R5] by adding a tertiary interval, consistent with centralised sarcoma care pathways.

Data extraction and synthesis {#s2-4}
-----------------------------

Study design, inclusion period, study population, length of total interval and its components, and effect of total interval on outcomes, such as metastases at diagnosis, overall survival and HRQoL, were extracted from included articles. Factors influencing length of total interval or its components were extracted and organised as tumour-specific factors (eg, histology), patient specific (eg, age) or healthcare related (eg, available imaging studies). Based on our clinical experience, previous reports and different healthcare providers treating these groups of patients, we expected to find different results for bone sarcoma (BS) and soft tissue sarcoma (STS), and data were thus presented in separate tables. Due to the heterogeneity of inclusion criteria and methods, it was not possible to conduct a meta-analysis, so results were reported descriptively.

Results {#s3}
=======

Included articles {#s3-1}
-----------------

Our search yielded 2304 unique hits. The reference lists of relevant articles were searched for additional studies which resulted in six additional publications versus and OH screened titles and abstracts of these 2310 publications, 109 studies met the inclusion criteria. After careful independent full-text screening by versus and OH, 62 studies were included in this review. The flow chart of this selection procedure is presented in [figure 2](#F2){ref-type="fig"}.

![Selection procedure. BS, bone sarcoma; STS, soft tissue sarcomas.](esmoopen-2019-000592f02){#F2}

Bone sarcomas {#s3-2}
-------------

### Length of total interval {#s3-2-1}

Thirty-four studies involving a total of 17 258 patients investigated the total interval in BS ([table 1](#T1){ref-type="table"})[@R8]; five of these studies prospectively collected follow-up data. A broad range in the length of the total interval was found, which varied from 9 to 120.4 weeks.

###### 

Diagnostic intervals in bone sarcoma

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author;\                           Study design, inclusion period and country       Study population                                Age (years)           Patient interval in weeks   Primary care interval in weeks   Secondary care interval in weeks   Tertiary care interval in weeks   Diagnostic interval in weeks   Total interval in weeks
  year                                                                                                                                                                                                                                                                                                                       
  ---------------------------------- ------------------------------------------------ ----------------------------------------------- --------------------- --------------------------- -------------------------------- ---------------------------------- --------------------------------- ------------------------------ -------------------------
  Kammerer 2012[@R8]                 Retrospective 1972--2010\                        36 osteosarcoma of jaw                          33.9\                 15.9 (4.3--103.2)\*†        NR                               NR                                 NR                                NR                             NR
                                     Germany                                                                                          (2-81)\*†                                                                                                                                                                              

  Pan\                               Retrospective 2003--2008\                        30 osteosarcoma around the knee joint           17\                   10 (0--49)\*†               5\*                              5 (0--24)\*†                       2\*                               NR                             17 (4--55)\*†
  2010[@R9]                          Malaysia                                                                                         (9-34)\*†                                                                                                                                                                              

  Widhe\                             Retrospective 1980--2002\                        106 chest wall chondrosarcoma                   57\*                  12.9 (0--507.4)‡†           19.35 (0.43--847.1)‡†            NR                                 NR                                NR                             34.4 (4.3--855.7)‡†
  2010[@R10]                         Sweden                                                                                                                                                                                                                                                                                  

  Goyal\                             Retrospective 1990--2002\                        103 bone sarcoma                                15 (4--22)‡†          4.3‡                        NR                               NR                                 NR                                6.88‡                          16.34 (4.3--197.8)‡†
  2004[@R11]                         UK                                                                                                                                                                                                                                                                                      

  Widhe\                             Retrospective 1981--2000\                        26 Ewing sarcoma of the rib                     16 (6--26)‡†          10.75 (0--43)‡†             12.9 (0--43)‡†                   NR                                 NR                                NR                             NR
  2007[@R13]                         Sweden                                                                                                                                                                                                                                                                                  

  Widhe\                             Retrospective 1983--1995\                        102 osteosarcoma                                15.8 (5.5--29.5)\*†   6 (1--26)\*†                9 (1--52)\*†                     NR                                 NR                                NR                             15 (2--75)\*†
  [@R12]                             Sweden                                                                                                                                                                                                                                                                                  

  47 Ewing sarcoma                   15.4 (2.5--26.0)\*†                              15 (1--100)\*†                                  19 (1--72)\*†         NR                          NR                               NR                                 34 (3--150)\*†                                                   

  Guerra\                            Retrospective 1985--2001\                        198 osteosarcoma                                15.7\*                NR                          NR                               NR                                 NR                                NR                             22.6\*
  2006[@R14]                         Brazil                                                                                                                                                                                                                                                                                  

  55 Ewing sarcoma                   12.8\*                                           NR                                              NR                    NR                          NR                               NR                                 34.8\*                                                           

  Brotzmann 2013[@R15]               Retrospective 1969--2008\                        32 bone sarcoma of the foot                     NR                    NR                          NR                               NR                                 NR                                NR                             43‡
                                     Switzerland                                                                                                                                                                                                                                                                             

  15 chondrosarcoma                  NR                                               NR                                              NR                    NR                          NR                               NR                                 32.3‡                                                            

  9 osteosarcoma                     NR                                               NR                                              NR                    NR                          NR                               NR                                 64.5‡                                                            

  8 Ewing sarcoma                    NR                                               NR                                              NR                    NR                          NR                               NR                                 77.4‡                                                            

  Biscaglia\                         Retrospective 1983--1999\                        12 osteosarcomas of the foot                    33\                   50%§                        NR                               NR                                 NR                                NR                             120.4 (6--48)\*†
  1998[@R16]                         Italy                                                                                            (17-64)\*†                                                                                                                                                                             

  Bacci\                             Retrospective 1979--1997 Italy                   618 Ewing sarcoma                               NR                    13\*                        NR                               NR                                 NR                                4\*                            18\*
  1999[@R17]                                                                                                                                                                                                                                                                                                                 

  Bacci\                             Retrospective 1983--1999\                        965 high-grade osteosarcoma of the extremity    NR                    5.2\*                       NR                               NR                                 NR                                4.8\*                          10.5 (1--59)\*†
  2000[@R19]                         Italy                                                                                                                                                                                                                                                                                   

  810 localised                      6.0\*                                            NR                                              NR                    NR                          NR                               10.7\*                                                                                              

  155 metastasized disease           4.1\*\                                           NR                                              NR                    NR                          NR                               9.0\*\                                                                                              
                                     (p\<0.00017)                                                                                                                                                                        (p\<0.016)                                                                                          

  Bacci\                             Retrospective 1980--1999\                        1071 high-grade osteosarcoma of the extremity   \<15: n=501¶\         NR                          NR                               NR                                 NR                                NR                             NR
  2002[@R18]                         Italy                                                                                            ≥15: n=570¶                                                                                                                                                                            

  891 localised disease                                                               NR                                              NR                    NR                          NR                               NR                                 10.9\*                                                           

  180 metastasized disease                                                            NR                                              NR                    NR                          NR                               NR                                 9.3\* (p\<0.0002)                                                

  Bacci\                             Retrospective 1983--2006\                        888 Ewing sarcoma family tumour                 \<12: n=160¶\         NR                          NR                               NR                                 NR                                NR                             75%§
  2007[@R20]                         Italy                                                                                            ≥12: n=728¶                                                                                                                                                                            

  Goedhart\                          Retrospective 2000--2012\                        102 high-grade bone sarcoma                     30.0\                 NR                          NR                               NR                                 NR                                NR                             NR
  2016[@R21]                         The Netherlands                                                                                  (5-89)\*†                                                                                                                                                                              

  19 chondrosarcoma                                                                   34.9\* (p\<0.05)                                28.2\*                7.1\* (p\<0.05)             5\*                              NR                                 98,3\*                                                           

  29 Ewing sarcoma                   5.9\*                                            14.8\*                                          2.3\*                 3.5\*                       NR                               22.9\* (p\<0.01)                                                                                    

  54 osteosarcoma                    6.4\*                                            8.3\*                                           2.4\*                 3.8\*                       NR                               23.3\* (p\<0.01)                                                                                    

  Brasme 2014[@R22]                  Prospective 1988--2000\                          436 Ewing sarcoma                               12‡                   NR                          NR                               NR                                 NR                                NR                             10‡
                                     France                                                                                                                                                                                                                                                                                  

  Kim\                               Retrospective 1985--2005\                        26 osteosarcoma and doctor delay \>45 days      30.2 (4--67)\*†       NR                          NR                               NR                                 NR                                45.2\*                         NR
  2009[@R23]                         Korea                                                                                                                                                                                                                                                                                   

  Simpson\                           Retrospective 1965--2005\                        19 Ewing sarcoma of upper limb                  19 (3--57)\*†         25.8 (4.3--774)‡†           NR                               NR                                 NR                                5 (1--128)‡†                   35 ‡
  2005[@R24]                         Scotland                                                                                                                                                                                                                                                                                

  Wurtz\                             Retrospective 1975--1995\                        68 bone sarcoma of pelvic girdle                41 (8--82)‡†          NR                          NR                               NR                                 NR                                NR                             43^3^\
  1999[@R25]                         USA                                                                                                                                                                                                                                                                                     25.8 (4.3--206.4)‡†

  Sneppen\                           Retrospective 1962--1979\                        84 osteosarcoma                                 28 (8--86)\*†         6.9\*                       NR                               NR                                 NR                                7.3\*                          27.5 (8.6--154.8)\*†
  1984[@R26]                         Denmark                                                                                                                                                                                                                                                                                 

  40 Ewing sarcoma                   17 (2--62)\*†                                    6.5\*                                                                 32.3\*                      41.3 (4--206.4)\*†                                                                                                                   

  Nandra\                            Retrospective 1985--2010\                        2360 bone sarcomas                              22‡                   NR                          NR                               NR                                 NR                                NR                             16 ‡
  2015[@R27]                         UK                                                                                                                                                                                                                                                                                      

  Vadillo\                           Retrospective 1952--2007\                        135 bone sarcomas of the jaw                    31 (1--80)\*†         13\*                        19.7\*                           NR                                 17.4\*                            NR                             50.1\*
  2011[@R28]                         Peru                                                                                                                                                                                                                                                                                    

  Ashwood\                           Prospective 1997--1998\                          100 tumour service                              36.3\*                63.6 (0--111.8)\*†          NR                               NR                                 NR                                58 (2,3--516)\*†               NR
  2003[@R29]                         UK                                                                                                                                                                                                                                                                                      

  49 malignant disease: 47 sarcoma   NR                                               32.7 (2.2--47.3)\*†                             32.3 (0--55.9)\*†     NR                          NR                               NR                                 NR                                                               

  George\                            Retrospective 2011\                              107 sarcoma of which                            ≥18\*                 4.3‡                        NR                               NR                                 NR                                13.7‡                          NR
  2012[@R30]                         UK                                                                                                                                                                                                                                                                                      

  41 bone sarcoma                    6.5 (0--3096)‡†                                  16.8 (1.5--211.6)‡†                             NR                    NR                          NR                               NR                                                                                                  

  Martin\                            Retrospective 2001--2003\                        235 patients;                                   22.2 (15--29)\*†      NR\                         NR\                              NR\                                NR\                               NR                             10.7\*
  2007[@R31]                         USA                                                                                                                    NR\                         NR\                              NR\                                NR\                                                              
                                                                                                                                                            NR                          NR                               NR                                 NR                                                               

  66 with sarcoma                    NR                                               20.3\*                                                                                                                                                                                                                                 

  30 bone sarcoma                    NR                                               15.7\*                                                                                                                                                                                                                                 

  Smith\                             Prospective 1985--2009\                          2568 bone sarcomas                              25‡                   NR                          NR                               NR                                 NR                                NR                             16‡
  2011[@R32]                         UK                                                                                                                                                                                                                                                                                      

  Grimer\                            Prospective 1986--2006\                          1460 bone sarcoma                               NR                    NR                          NR                               NR                                 NR                                NR                             16‡
  2006[@R33]                         UK                                                                                                                                                                                                                                                                                      

  Lawrenz\                           Retrospective 1990--2014\                        bone sarcoma:\                                  30.7\*                NR                          NR                               NR                                 NR                                NR                             16‡\
  2018[@R41]                         UK                                               1446 non-metastatic\                                                                                                                                                                                                                   45.8\* vs\
                                                                                      346 metastatic                                                                                                                                                                                                                         29.9\*

  Balmant\                           Retrospective 2007--2011\                        1257 osteosarcoma and Ewing sarcoma             0-29¶                 NR                          NR                               NR                                 NR                                NR                             NR
  2018[@R40]                         Brazil                                                                                                                                                                                                                                                                                  

  0-14¶ (46%)                        NR                                               NR                                              NR                    NR                          1.1‡                             NR                                                                                                  

  15--19¶ (33%)                      NR                                               NR                                              NR                    NR                          1.3‡                             NR                                                                                                  

  20--29¶ (21%)                      NR                                               NR                                              NR                    NR                          1.9‡                             NR                                                                                                  

  Bielack\                           Retrospective 1980--1998 German/Austrian/Swiss   1702 high-grade osteosarcomas                   16.7†                 NR                          NR                               NR                                 NR                                9.9‡                           NR
  2002[@R39]                                                                                                                                                                                                                                                                                                                 

  Chen\                              Retrospective 2004--2012\                        364 malignancies of which\                      16.5‡                 NR                          NR                               NR                                 NR                                NR                             12.4‡
  2017[@R34]                         USA                                              30 bone sarcoma                                                                                                                                                                                                                        

  Desandes\                          Retrospective 2012--2013\                        993 malignancies of which\                      NR                    NR                          NR                               NR                                 NR                                NR                             NR
  2018[@R35]                         France                                           48 bone sarcoma                                                                                                                                                                                                                        

  15--19 (n=33)¶                     NR                                               NR                                              NR                    NR                          NR                               10.1‡                                                                                               

  20--24 (n=15)¶                     NR                                               NR                                              NR                    NR                          NR                               21.4‡                                                                                               

  Petrilli\                          Prospective 1987--1996\                          209 high-grade osteosarcomas                    14 (2.4--24.5)\*†     NR                          NR                               NR                                 NR                                NR                             18.4\*
  2006[@R36]                         Brazil                                                                                                                                                                                                                                                                                  

  Yang\                              Retrospective 1994--2005\                        51 osteosarcoma                                 13 (3--20)‡†          4.3 (0--51.4)‡†             NR                               NR                                 NR                                3 (0--50)‡†                    8.7 (0--51.6)‡†
  2009[@R37]                         Hong Kong                                                                                                                                                                                                                                                                               

  Younger\                           Retrospective 2015\                              558 sarcoma of which\                           64.1 (18--96)\*†      56.7%§                      NR                               NR                                 NR                                NR                             NR
  2018[@R38]                         UK                                               140 bone sarcoma                                                                                                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Mean.

†Range within brackets.

‡Median.

§% of delays attributed to this interval.

¶Included age group.

NR, not reported.

### Components of the total interval {#s3-2-2}

The impact of patient intervals was measured in 19 studies (mean 4.1--34.1 weeks), eight studies measured the primary care interval (mean 5--32.3 weeks), whereas the secondary (mean 2.3--7.1 weeks) and tertiary care intervals (mean 2--17.4 weeks) were measured in two and three studies respectively ([table 1](#T1){ref-type="table"}).

### Effect of tumour-specific factors {#s3-2-3}

Several factors were studied as determinants of the length of the total interval. Interestingly, tumour-specific factors such as tumour size or grade did not appear to influence the length of total interval.[@R22] Patients with sarcomas located in the trunk were shown to have a longer interval than those who have sarcomas in the extremities (29 vs 14 weeks; p\<0.001) by Lawrenz *et al* (n=1792).[@R41]

Tumour histology was found to be of influence on the total interval. Goedhart *et al* performed a retrospective study among 102 patients with high-grade BS and reported a significantly longer patient interval and secondary care interval for chondrosarcoma versus Ewing sarcoma and osteosarcoma,[@R21] which resulted in a significantly longer total interval, with a mean of 98.3 weeks for chondrosarcoma, versus 22.9 and 23.3 weeks for Ewing sarcoma and osteosarcoma, respectively.

Four other studies reported similar results on total intervals for Ewing sarcoma and osteosarcoma; all had a trend towards a longer diagnostic pathway for patients with Ewing sarcoma.[@R12] In a study by Widhe *et al* (n=106), the longer diagnostic pathway in Ewing sarcoma was a result of both a longer patient and primary care component[@R12] whereas a study by Sneppen *et al* (n=124), reported a four times longer diagnostic interval for Ewing sarcoma than for osteosarcoma patients despite similar patient intervals.[@R26] Lawrenz *et al* illustrated that intermediate-grade tumours had a longer diagnostic interval (52 weeks) compared with high-grade BS (12 weeks; p\<0.001).[@R41] In contrast, a study focusing only on BS of the foot (n=32) presented opposite results: a median total interval of 32.3 weeks for chondrosarcoma, vs 64.5 weeks and 77.4 weeks for osteosarcoma and Ewing sarcoma, respectively.[@R15] Another small study (n=6) reported that half of patients with osteosarcoma of the foot had a considerable patient delay, resulting in a mean total interval of 120.4 weeks.[@R16]

### Effect of patient-specific factors {#s3-2-4}

Gender was not associated with the length of the total interval in four studies,[@R12] however, there was evidence that patient age was a factor. Six studies reported a significantly longer total interval for older teenagers, adolescents or adults compared with younger children or (younger) teenagers (\<12 vs ≥12--22 years[@R11] [@R22]; \<20 vs ≥20--86 years[@R26]; \<22 vs ≥22 years[@R27]; 0--14 vs 15--19 vs 20--29 years[@R40]; \<12 versus ≥12 years[@R11]). Furthermore, Desandes *et al* found young adults were more at risk for a longer total interval than patients in puberty (15--19 vs 20--24 years; 10.1 vs 21.4 weeks respectively; p=0.04).[@R35] Lawrenz *et al* (n=1792) investigated age (mean 30.7 years) as a continuous variable and reported every additional year of age was associated with a 1.3 weeks longer total interval (p\<0.00).[@R41] In contrast Guerra *et al* (n=253) found no significant relationship between age (range 0--30 years) and the length of the total interval.[@R14] Younger *et al* found no relationship between age and patient interval nor diagnostic interval.[@R38]

The presenting symptom did not predict the length of the total interval in four studies.[@R12] Study results (n=4) on the influence of pain symptoms on the total interval are contradictory, with some studies suggesting a shortening of the interval, no influence or even a longer total interval.[@R12]

### Effect of healthcare system-related factors {#s3-2-5}

The influence of the year of first presentation was studied in five studies. None showed evidence of shortening total intervals over the past 30--50 years,[@R10] [@R14] despite advances in healthcare models including the introduction of cancer pathways and dedicated specialist sarcoma centres.

The location of first presentation to a healthcare professional was investigated among patients with Ewing sarcoma. The diagnostic interval was significantly longer when presenting to a general practitioner (GP) compared with the accident & emergency department (p=0.04).[@R11]

The influence of radiology and pathology investigations on the diagnostic interval were reported in two studies.[@R10] When no imaging studies were ordered at the patient's first contact with a healthcare professional, a longer diagnostic interval was observed. When imaging was incorrectly interpreted as normal, which was the case in 35% of patients with chondrosarcoma at non-specialist centres, this resulted in an even longer diagnostic interval (21 vs 9.5 months). At non-specialist centres, only 26% (n=39) of chondrosarcomas biopsied were correctly diagnosed as malignant, while at specialist sarcoma centres, 94% (n=34) were correctly diagnosed.[@R10] A descriptive study by Ashwood *et al* highlighted how imaging studies performed prior to referral to a specialist centre often had to be repeated because they did not provide all the required information, and biopsies or surgeries performed by the referring teams often complicated the patient's subsequent management.[@R29]

A qualitative study in Malaysia by Pan *et al* (n=30) demonstrated the multifactorial nature of diagnostic delay, which was dependent on the patient perception of symptoms and complaints, the influence of traditional healers and the proximity of health clinics.[@R9] A Brazilian study with 1257 BS patients found differences in diagnostic intervals between geographic regions, possibly explained by the availability of CT scan equipment and the difference in number of hospital beds per region.[@R40]

### Relationship between total interval and outcomes {#s3-2-6}

The influence of delay on clinical outcomes of BS patients has been investigated in 20 of the 34 included BS studies ([table 2](#T2){ref-type="table"}).[@R10]

###### 

The effect of diagnostic interval on stage or metastases at diagnosis, or overall survival (OS) for bone sarcomas

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author;\                   Study design, inclusion period and country   Study population                                   Age (years)                Total interval in weeks   Stage of disease or metastases at diagnosis                                                                                              OS
  year                                                                                                                                                                                                                                                                                                                     
  -------------------------- -------------------------------------------- -------------------------------------------------- -------------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Widhe\                     Retrospective\                               106 chest wall chondrosarcoma                      57\*                       34.4 (4.3--855.7)†‡       NR                                                                                                                                       Patients who died from chondrosarcoma had interval \>8 months (p\<0.05)
  2010[@R10]                 1980--2002\                                                                                                                                                                                                                                                                                   
                             Sweden                                                                                                                                                                                                                                                                                        

  Goyal\                     Retrospective\                               103 bone sarcoma                                   15 (4--22)†‡               16.34 (4.3--197.8)†‡      NR                                                                                                                                       No association
  2004[@R11]                 1990--2002\                                                                                                                                                                                                                                                                                   
                             UK                                                                                                                                                                                                                                                                                            

  Brotzmann\                 Retrospective\                               32 bone sarcoma of the foot                        NR                         43†                       No association                                                                                                                           No association
  2013[@R15]                 1969--2008\                                                                                                                                                                                                                                                                                   
                             Switzerland                                                                                                                                                                                                                                                                                   

  Bacci\                     Retrospective\                               618 Ewing sarcoma                                  NR                         18 ‡                      Stage: no association\                                                                                                                    
  1999[@R17]                 1979--1997\                                                                                                                                          Interval \<2 months, more metastases (32 vs 12% p\<0.0001)                                                                               
                             Italy                                                                                                                                                                                                                                                                                         

  Bacci\                     Retrospective\                               965 high-grade osteosarcoma extremity              NR                         10.5 (1--59)\*‡           NR                                                                                                                                       No association
  2000[@R19]                 1983--1999\                                                                                                                                                                                                                                                                                   
                             Italy                                                                                                                                                                                                                                                                                         

  Bacci\                     Retrospective\                               High-grade osteosarcoma extremity\                 \<15: n=501§ ≥15: n=570§   10.9\*                    45.2% diagnostic interval \<2 months                                                                                                     NR
  2002[@R18]                 1980--1999\                                  891 localised disease                                                                                                                                                                                                                            
                             Italy                                                                                                                                                                                                                                                                                         

  180 metastasized disease   9.3\* (p\<0.0002)                            56.1% diagnostic interval \<2 months (p\<0.0009)                                                                                                                                                                                                 

  Bacci\                     Retrospective\                               888 Ewing sarcoma family tumour                    \<12: n=160§\              \<2 months: n=215§        35.5% metastatic disease                                                                                                                 NR
  2007[@R20]                 1983--2006\                                                                                     ≥12: n=728§                                                                                                                                                                                   
                             Italy                                                                                                                                                                                                                                                                                         

  ≥2 months: n=658§          15.9% metastatic disease\                    NR                                                                                                                                                                                                                                               
                             (p\<0.0001)                                                                                                                                                                                                                                                                                   

  Goedhart\                  Retrospective\                               19 chondrosarcoma                                  30.0\                      98.3\*                    **Metastatic disease**\                                                                                                                  **5 years OS**\
  2016[@R21]                 2000--2012\                                                                                     (5--89)\*‡                                           10.5%                                                                                                                                    60.9%
                             The Netherlands                                                                                                                                                                                                                                                                               

  29 Ewing sarcoma           22.9\*\                                      37.9%                                              49%                                                                                                                                                                                           
                             (p\<0.01)                                                                                                                                                                                                                                                                                     

  54 osteosarcoma            23.3\* (p\<0.01)                             24.1%                                              67%                                                                                                                                                                                           

  Brasme\                    Prospective\                                 436 Ewing sarcoma                                  12†                        10†                       No association                                                                                                                           No association
  2014[@R22]                 1988--2000\                                                                                                                                                                                                                                                                                   
                             France                                                                                                                                                                                                                                                                                        

  Kim\                       Retrospective\                               26 osteosarcoma and doctor delays \>45 days        30.2 (4--67)\*‡            NR                        NR                                                                                                                                       **5 years OS:** 26%\
  2009[@R23]                 1985--2005\                                                                                                                                                                                                                                                                                   **10 years OS:** 10%
                             Korea                                                                                                                                                                                                                                                                                         

  Simpson\                   Retrospective\                               19 Ewing sarcoma of upper limb                     19 (3--57)\*‡              35†                       A higher Enneking stage resulted in greater mortality (p=0.02)                                                                           NR
  2005[@R24]                 1965--2005\                                                                                                                                                                                                                                                                                   
                             Scotland                                                                                                                                                                                                                                                                                      

  Wurtz\                     Retrospective\                               68 bone sarcoma of pelvic girdle                   41 (8--82)\*‡              43‡                       No association                                                                                                                           No association
  1999[@R25]                 1975--1995\                                                                                                                                                                                                                                                                                   
                             USA                                                                                                                                                                                                                                                                                           

  Nandra\                    Retrospective\                               2668 bone sarcoma                                  22†                        16†                       No association                                                                                                                           No association
  2015[@R27]                 1985--2010\                                                                                                                                                                                                                                                                                   
                             UK                                                                                                                                                                                                                                                                                            

  Vadillo\                   Retrospective\                               135 bone sarcoma of the jaw                        31 (1--80)\*‡              50.1\*                    NR                                                                                                                                       No association
  2011[@R28]                 1952--2007\                                                                                                                                                                                                                                                                                   
                             Peru                                                                                                                                                                                                                                                                                          

  Martin\                    Retrospective\                               30 bone sarcoma                                    22.2 (15--29)\*‡           15.7\*                    Osteosarcoma: diagnostic interval 259 days longer for patients with advanced stage disease than those with localised disease (p\<0.01)   NR
  2007[@R31]                 2001--2003\                                                                                                                                                                                                                                                                                   
                             USA                                                                                                                                                                                                                                                                                           

  Grimer\                    Prospective\                                 1460 bone sarcoma                                  NR                         16†                       NR                                                                                                                                       No association
  2006[@R33]                 1986--2006\                                                                                                                                                                                                                                                                                   
                             UK                                                                                                                                                                                                                                                                                            

  Lawrenz\                   Retrospective\                               Bone sarcoma\                                      30.7\*                     16†                       No association                                                                                                                           Non-metastatic cohort: longer interval, better survival (HR 0.996). No association \>or \< 4 months.
  2018[@R41]                 1990--2014\                                  1446 non-metastatic\                                                                                                                                                                                                                             
                             UK                                           346 metastatic                                                                                                                                                                                                                                   

  45.8\* vs\                 P=0.009                                                                                                                                                                                                                                                                                       
  29.9\*                                                                                                                                                                                                                                                                                                                   

  Bielack\                   Retrospective\                               1702 high grade osteosarcoma                       16.7\*                     9.9†                      Longer diagnostic interval: more primary metastases (p=0.007)                                                                            No association
  2002[@R39]                 1980--1998\                                                                                                                                                                                                                                                                                   
                             German/Austrian/Swiss                                                                                                                                                                                                                                                                         

  Petrilli\                  Prospective\                                 209 high grade osteosarcoma                        14 (2.4--24.5)\*‡          18.4\*                    No association                                                                                                                           No association
  2006[@R36]                 1987--1996\                                                                                                                                                                                                                                                                                   
                             Brazil                                                                                                                                                                                                                                                                                        

  Yang\                      Retrospective\                               51 osteosarcoma                                    13 (3--20)†‡               8.7 (0--51.6)†‡           No association                                                                                                                           No association
  2009[@R37]                 1994--2005\                                                                                                                                                                                                                                                                                   
                             Hong Kong                                                                                                                                                                                                                                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Mean.

†Median.

‡Range within brackets.

§Included group.

In 12 of these studies (n=7414), no significant association between length of the total interval (mean total interval between 8.7 and 50.1 weeks) and overall survival was found.[@R11] However, one of these studies (n=1702) found that patients with a longer total interval more often had metastatic disease at diagnosis than those with a short total interval.[@R39]

One study of 965 high-grade osteosarcomas of the extremities diagnosed between 1983 and 1999, identified an inverse relationship between the total interval and the stage of disease[@R19]; the patient interval was significantly shorter in patients with metastatic disease compared with patients with localised disease (4.1 vs 6.0 weeks), ultimately resulting in a shorter total interval (9.0 vs 10.7 weeks). The total interval was significantly shorter in patients who later relapsed than in patients who remained free of disease after 5 years. However, this difference lost significance when patients were analysed according to disease stage at presentation. In a secondary analysis of this patient population, including patients diagnosed between 1980 and 1983 (n=1071),[@R18] patients with a diagnostic interval \<2 months were significantly more likely to have metastases at diagnosis than those with a longer interval (56.1% vs 45.2%; p\<0.0009).

Two other studies by the same research group in patients with Ewing sarcoma and Ewing sarcoma family of tumours (ESFT), both demonstrated that a diagnostic interval \<2 months was associated with an increased likelihood of metastases at diagnosis ([table 2](#T2){ref-type="table"}),[@R17] impact on overall survival was not reported.

A study with 1792 BS patients showed that a longer duration of symptoms was associated with longer survival (HR 0.996, 95% CI 0.994 to 0.998).[@R41] This continuous association was lost when patients were compared in categories (\<or \>4 months; HR 0.935 95% CI 0.743 to 1.177).

In contrast, four studies with a combined number of 386 patients with chondrosarcoma, osteosarcoma and Ewing sarcoma, and mean total intervals between 10.7 and 35 weeks, reported a negative impact of a long total interval on stage and survival.[@R10]

No study has reported on the association between length of the total interval on patient-reported outcomes including HRQoL.

Soft tissue sarcoma {#s3-3}
-------------------

### Length of total interval {#s3-3-1}

Thirty-six studies investigated the total interval for STS ([table 3](#T3){ref-type="table"}).[@R27] A combined total of 16 845 patients were included and, reflecting STS heterogeneity, the total interval varied tremendously; between 4.3 and 614.9 weeks.

###### 

Length of diagnostic intervals for STS

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author;\                     Study design, time period and country   Study\                                                Age (years)          Patient\               Primary\               Secondary care\    Tertiary care interval (weeks)   Diagnostic interval (weeks)   Total interval (weeks)
  year                                                                 population                                                                 interval (weeks)       care\                  interval (weeks)                                                                  
                                                                                                                                                                         interval (weeks)                                                                                         
  ---------------------------- --------------------------------------- ----------------------------------------------------- -------------------- ---------------------- ---------------------- ------------------ -------------------------------- ----------------------------- --------------------------
  Gofman\                      Retrospective 1991--2004\               73 synovial sarcoma                                   38 (8--82)\*†        NR                     NR                     NR                 NR                               NR                            77.4 (8.6--202.1)\*†
  2007[@R61]                   Israel                                                                                                                                                                                                                                             

  Amant\                       Retrospective 1990--2002\               6 endometrial stromal sarcoma                         34\*                 NR                     NR                     NR                 NR                               NR                            614.9 (103.2--1754.4)\*†
  2003[@R62]                   Belgium                                                                                                                                                                                                                                            

  Nakamura\                    Retrospective 2001--2009\               100 STS, referred for additional resection            57 (0--89)‡\*        12.9 (4.3--309.6)\*†   NR                     NR                 NR                               15%§                          25.8 (4--310)\*†
  2011[@R63]                   Japan                                                                                                                                                                                                                                              

  Pawlik\                      Retrospective 1975--2002\               29 angiosarcoma of the scalp                          71\*                 NR                     NR                     NR                 NR                               NR                            21.9 (0--73.5)\*†
  2003[@R64]                   USA                                                                                                                                                                                                                                                

  Rougraff\                    Retrospective 1992--2007\               381 grade 3 STS of extremity or flank                 NR                   NR                     NR                     NR                 NR                               NR                            66.6‡\
  2012[@R65]                   USA                                                                                                                                                                                                                                                20\*

  Rougraff\                    Retrospective 1992--2003\               624 sarcoma:\                                         NR                   NR                     NR                     NR                 NR                               NR                            NR
  2006[@R69]                   USA                                     382 soft-tissue sarcoma                                                                                                                                                                                    

  278 high-grade STS           73.3 (0.25--362.8)‡†                                                                                                                                                                                                                               

  104 low-grade STS            127.4 (0.25--256)‡†                                                                                                                                                                                                                                

  Singla\                      Retrospective 1990--2011\               72 angiosarcoma                                       65 (19--93)\*†       NR                     NR                     NR                 NR                               NR                            0-154.8†\
  2014[@R66]                   USA                                                                                                                                                                                                                                                41%§

  Ferrari\                     Retrospective 1977--2005 Italy          575 STS                                               ≤21¶                 NR                     NR                     NR                 NR                               NR                            8.6\
  2010[@R67]                                                                                                                                                                                                                                                                      (1--258)\*†

  Pratt\                       Retrospective 1962--1976\               46 rhabdyomyosarcoma of head or neck                  5.9 (0.3--20.5)\*†   NR                     NR                     NR                 NR                               NR                            4.3--19.3\*
  1978[@R42]                   USA                                                                                                                                                                                                                                                

  Bandyopadhyay\               Retrospective 1991--2010\               391 primary pulmonary artery sarcoma                  52 (14--94)\*†       NR                     NR                     NR                 NR                               NR                            14.3\*
  2016[@R43]                   USA                                                                                                                                                                                                                                                

  Brouns\                      Retrospective 1999--2001\               100 STS                                               50.5 (3--88)\*†      17.2 (8.6--1032)\*†    NR                     NR                 NR                               25.8 (8.6--339.7)\*†          NR
  2003[@R44]                   Belgium                                                                                                                                                                                                                                            

  Chandu\                      Retrospective 1955--1999\               109 STS                                               33.4\                NR                     NR                     NR                 NR                               86‡                           NR
  2003[@R45]                   Scotland                                                                                      (10-77)‡†                                                                                                                                            

  Clark\                       Prospective 2003--2004\                 31 STS with referral \>3 months (19.5%)               59 (34--84)‡†        NR                     NR                     NR                 NR                               94.6 (17.2--412.8)‡†          NR
  2005[@R46]                   UK                                                                                                                                                                                                                                                 

  Johnson\                     Prospective/recall\                     162 STS                                               53 (16--88)‡†        1.3\*\                 2.4\*                  6.9\*                                               25.0\*\                       40.4\*\
  2008[@R47]                   2005\                                                                                                              28.6‡                                                                                             83.1‡                         112.3‡
                               UK                                                                                                                                                                                                                                                 

  Lawrence\                    Retrospective 1977--1978\               2355 STS and\                                         \>18¶                NR                     NR                     NR                 NR                               4.3\*                         17.2\*
  1986[@R48]                   and 1983--1984                          3457 STS                                                                                                                                                                                                   

  Park\                        Retrospective 1997--2008\               18 grade 3 STS of the extremity with delay \>1 year   44.8\                NR                     NR                     NR                 NR                               NR                            (51.6-154.8)†
  2010[@R49]                   Korea                                                                                         (15-79)‡†                                                                                                                                            

  Seinen\                      Retrospective 2003--2009\               33 retroperitoneal sarcoma (1 GIST)                   66\                  3.3 (0--73.1)\*†       2.1\                   5.1\               1.1 (0.1--69)\*†                 13.4 (4.3--172)\*†            NR
  2010[@R50]                   Sweden                                                                                        (21-86)‡†                                   (0--34.9)\*†           (0.3--160)\*†                                                                     

  Bruun\                       Retrospective 1962--1974\               7 oral sarcoma                                        29\                  6.9‡                   NR                     NR                 NR                               15.9‡                         NR
  1976[@R51]                   Denmark                                                                                       (10-81)‡†                                                                                                                                            

  Cooper\                      Retrospective 1984--1993\               18 STS interval \>4 weeks                             43\                  36%§                   23%§                   11%§               NR                               28\*                          NR
  1996[@R52]                   Ireland                                                                                       (2-89)\*†                                                                                                                                            

  Antillon\                    Retrospective 2000--2007\               47 rhabdo-myosarcoma                                  6 (1--17)\*†         NR                     NR                     NR                 NR                               NR                            8.6 (2--51.6)\*†
  2008[@R53]                   Guatemala                                                                                                                                                                                                                                          

  33 non-rhabdo-myosarcoma     11 (2--17)\*†                           25.8 (3--154.8)\*†                                                                                                                                                                                         

  Chotel\                      Retrospective 1985--2006\               33 synovial sarcoma                                   12.3\                43 (0--156)‡†          NR                     NR                 NR                               50 (0--362)‡†                 98 (2--364)‡†
  2008[@R54]                   UK                                                                                            (3-16)‡†                                                                                                                                             

  Durve 2004[@R55]             Retrospective 1980--2000\               14 rhabdo-myosarcoma of ear and temporal bone         4.5 (1.0--8.6)‡†     NR                     NR                     NR                 NR                               NR                            21 (4--78)‡†
                               UK                                                                                                                                                                                                                                                 

  Watson 1994[@R56]            Retrospective 1985--1992\               40 STS of extremity                                   59 (14--87)\*†       NR                     NR                     NR                 NR                               NR                            16 weeks (2-104)\*†
                               Australia                                                                                                                                                                                                                                          

  Monnier 2006[@R57]           Retrospective 1982--2002\               66 dermatofibrosarcoma protuberans                    43\                  NR                     NR                     NR                 NR                               NR                            520.1 (8.3--2115.6)‡†
                               France                                                                                        (8-81)‡†                                                                                                                                             

  Dyrop 2013[@R60]             Retrospective 2007--2010\               258 STS                                               NR                   NR                     NR                     NR                 2007: 4\* 2010: 2.6\*            NR                            NR
                               Denmark                                                                                                                                                                                                                                            

  Buvarp Dyrop*l* 2016[@R59]   Retrospective 2014--2015\               545 referred patients of which:                       55 (0--93)\*‡        NR                     NR                     NR                 NR                               NR                            NR
                               Denmark                                                                                                                                                                                                                                            

  102 sarcoma patients\        11\*                                    2.4\*                                                 4.1\*                2.4\*                  NR                     25.1\*                                                                            
  (88 soft tissue\                                                                                                                                                                                                                                                                
  14 bone)                                                                                                                                                                                                                                                                        

  George\                      Retrospective 2011\                     66 STS                                                ≥18¶                 4.3 (0--516)\*‡        13.3 (1.7--154.8)\*‡   NR                 NR                               NR                            NR
  2012[@R30]                   UK                                                                                                                                                                                                                                                 

  Martin\                      Retrospective 2001--2003\               38 STS                                                22.2 (15--29)‡†      NR                     NR                     NR                 NR                               NR                            24.9‡
  2007[@R31]                   USA                                                                                                                                                                                                                                                

  Smith\                       Prospective 1985--2009\                 2366 STS                                              57\*                 NR                     NR                     NR                 NR                               NR                            26\*
  2011[@R32]                   UK                                                                                                                                                                                                                                                 

  Grimer\                      Prospective 1986--2006\                 1460 STS                                              NR                   NR                     NR                     NR                 NR                               NR                            26\*
  2006[@R33]                   UK                                                                                                                                                                                                                                                 

  Chen\                        Retrospective 2004--2012\               364 malignancies of which\                            14\*                 NR                     NR                     NR                 NR                               NR                            7.2\*
  2017[@R34]                   USA                                     18 STS                                                                                                                                                                                                     

  Nandra\                      Retrospective 1985--2010\               2277 STS                                              57\*                 NR                     NR                     NR                 NR                               NR                            26\*
  2015[@R27]                   UK                                                                                                                                                                                                                                                 

  Desandes\                    Retrospective 2012--2013\               993 malignancies of which\                            NR                   NR                     NR                     NR                 NR                               NR                            22.9^a^
  2018[@R35]                   France                                  43 STS                                                                                                                                                                                                     

  15--19†                      NR                                      NR                                                    NR                   NR                     NR                     15.4\*                                                                            

  20-24†                       NR                                      NR                                                    NR                   NR                     NR                     48.7\*                                                                            

  Smolle\                      Retrospective 1982--2014\               248 synovial sarcomas                                 37†                  NR                     NR                     NR                 NR                               NR                            52\*
  2019[@R68]                   UK                                                                                                                                                                                                                                                 

  \<16¶                        NR                                      NR                                                    NR                   NR                     NR                     49.8\*                                                                            

  ≥16¶                         NR                                      NR                                                    NR                   NR                     NR                     52\*                                                                              

  Younger*l*\                  Retrospective 2015\                     558 sarcoma of which\                                 64.1 (18--96) ‡†     46.8%§                 NR                     NR                 NR                               NR                            NR
  2018[@R38]                   UK                                      418 STS                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Median.

†Range within brackets.

‡Mean.

§Included age group.

¶% of delays attributed to this interval.

GIST, gastrointestinal stromal tumour; STS, soft tissue sarcomas.

### Components of the total interval {#s3-3-2}

Eleven studies examined the length of one or more components of the total interval.[@R30] Patient intervals varied between a median of 1.3--17.2 weeks, the primary care interval lasted 0.1--13.3 weeks, the secondary care interval varied between 1.1 and 6.9 weeks and the tertiary care interval was 2.1--7.9 weeks.

### Effect of tumour-specific factors {#s3-3-3}

Three studies found no relationship between tumour size and length of the total interval,[@R27] one study (n=575) in children and adolescents found that larger tumours were associated with a longer total interval (both for tumours \<5 vs ≥5 cm and \<10 vs ≥10 cm),[@R67] while a study in adults (n=162) reported that smaller tumours (median 8 cm) were associated with a longer total interval.[@R47]

Five studies reporting on the influence of tumour localisation have yielded contradictory results. Chotel *et al* (n=33) reported that synovial sarcoma of the knee or elbow had a longer total interval than tumours at other sites[@R54] and Smolle *et al* found synovial sarcomas located superficially had a longer interval than deeply located tumours (n=248; 2 years vs 12 months).[@R68] However, two other studies found no relationship between tumour site and total interval.[@R47] In children and adolescents, Ferrari *et al* (n=575) reported a longer total interval for STS of the extremities compared with tumours at other sites[@R67]; the authors attributed this difference to the underlying tumour histology, which for extremity tumours was more likely to consist of non-rhabdomyosarcomas and thus to encompass a broad spectrum of tumour biologies including low-grade STS. There are limited data specifically exploring the relationship between tumour histology and total interval, but Nandra *et al* (n=2 277) identifed that low-grade sarcomas were associated with a longer total interval.[@R27]

### Effect of patient-specific factors {#s3-3-4}

Patient gender, level of education and measures of social deprivation were not associated with length of total interval.[@R47] The effect of patient age was examined in five studies. Ferrari *et al* (n=575) established that children over 10 years old had a longer total interval than those younger than 10 years old.[@R67] Desandes *et al* (n=43) found the same result when comparing age groups 15--19 vs 20--24 years (15.4 vs 48.7 weeks; p=0.04).[@R35] Smolle *et al* found no difference for patients with synovial sarcoma older or younger than 16 years old.[@R68] A large retrospective study of almost 5000 sarcoma patients found no difference in total interval in patients older and younger than the median study age of 57 years.[@R27] A Sarcoma UK survey (n=558) established no association between age and patient interval or total interval.[@R38]

Two studies in children examined the effect of presenting symptoms on the total interval. The first (n=575) found no significant difference in the length of total interval between patients presenting with a swelling or with a specific symptom (eg, urethral obstruction).[@R67] The second in 33 patients with synovial sarcoma found the presence of a lump led to a shorter doctor interval, while a periarticular location or presence of a joint contracture led to both a longer patient and a longer doctor interval.[@R54]

### Effect of healthcare system-related factors {#s3-3-5}

The influence of the year of first presentation was studied in two publications, which did not find an improvement in total interval over the past 30--40 years.[@R54] [@R67]

In a study of 162 STS patients surveyed in 2005, the median patient interval was just 1.3 weeks, while the median primary care interval was 25.0 weeks[@R47]; if patients were reassured by the first medical professional they consulted (eg, their GP), it took twice as long to be referred on to an appropriate specialist centre.

Another single centre study of 545 patients with suspected sarcoma referred to a specialist clinic in Denmark reported a median total interval of 25.1 weeks[@R59]; 102 patients (19%) had a sarcoma (88 soft tissue, 14 BS), 68 patients (12%) had another malignancy.[@R58] Patients referred to the centre with prior investigations in their local hospital had a longer total interval than those with investigations in the sarcoma centre (median 13.3 vs 23.7 weeks). Synovial sarcoma patients with an unplanned resection had a longer diagnostic interval than those referred directly to a sarcoma centre (24 vs 12 months; p=0.001).[@R68]

### Relationship between total interval and patient outcomes {#s3-3-6}

The influence of the length of total interval on clinical outcomes in STS patients has been reported in 10 retrospective studies ([table 4](#T4){ref-type="table"}).[@R27]

###### 

The influence of length of the total interval on outcomes for STS

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref.                                 Study design, time period and country   Study population                             Age (years)      Total interval (weeks)   Influence on stage or metastases at diagnosis                                                                                                     Influence on survival
  ------------------------------------ --------------------------------------- -------------------------------------------- ---------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Gofman *et al*\                      Retrospective\                          73 synovial sarcoma                          38 (8--82)\*†    77.4 (8.6--202.1)\*†     NR                                                                                                                                                Total interval ≤1 year resulted in better systemic control (HR 0.3; p=0.037). No effect on overall survival.
  2007[@R61]                           1991--2004\                                                                                                                                                                                                                                                                      
                                       Israel                                                                                                                                                                                                                                                                           

  Amant *et al*\                       Retrospective\                          15 endometrial stromal sarcoma               34‡              NR                       Stage 4 disease in 5/6 with missed diagnosis, compared with 1/9 in correct diagnosis group. No data on diagnostic interval in the latter group.   NR
  2003[@R62]                           1990--2002\                                                                                                                                                                                                                                                                      
                                       Belgium                                                                                                                                                                                                                                                                          

  6 (40%) diagnosis initially missed   614.9 (103.2--1754.4)‡†                                                                                                                                                                                                                                                          

  Nakamura *et al*\                    Retrospective\                          100 STS, referred for additional resection   57 (0--89)‡†     25.843--17)\*‡           NR                                                                                                                                                5 years survival: 54.4%\
  2011[@R63]                           2001--2009\                                                                                                                                                                                                                                                                      (66.8% without metastases, 5.9% with metastases)
                                       Japan                                                                                                                                                                                                                                                                            

  \>6 months: n=43§                    12/43 metastases vs                     59.7% (34 patients without metastases)\                                                                                                                                                                                                  
                                                                               (p=0.04)                                                                                                                                                                                                                                 

  ≤6 months: n=57§                     6/51 metastases\                        77% (48 patients without metastases)                                                                                                                                                                                                     
                                       (p=0.048)                                                                                                                                                                                                                                                                        

  Rougraff *et al* 2012[@R65]          Retrospective\                          381 grade 3 STS of extremity or flank        NR               66.6 20‡\*               No association                                                                                                                                    No association
                                       1992--2007\                                                                                                                                                                                                                                                                      
                                       USA                                                                                                                                                                                                                                                                              

  Rougraff *et al* 2007[@R69]          Retrospective\                          624 sarcoma:\                                NR               NR                       No association                                                                                                                                    No association
                                       1992--2003\                             382 soft tissue sarcoma                                                                                                                                                                                                                  
                                       USA                                                                                                                                                                                                                                                                              

  278 high-grade STS                   73.3 (0.25--362.8)‡†                                                                                                                                                                                                                                                             

  104 low-grade STS                    127.4 (0.25--256)‡†                                                                                                                                                                                                                                                              

  Ferrari *et al*\                     Retrospective\                          575 STS                                      ≤21§             8.6\                     No association                                                                                                                                    Risk of death increased the longer the diagnostic interval (p=0.002)
  2010[@R67]                           1977--2005 Italy                                                                                      (1-258)\*†                                                                                                                                                                 

  Bandyopadhyay *et al*\               Retrospective\                          391 primary pulmonary artery sarcoma         52 (14--94)\*†   14.3\*                   NR                                                                                                                                                For every doubling diagnostic interval, the odds of death increased by 46% (p\<0.001)
  2016[@R43]                           1991--2010\                                                                                                                                                                                                                                                                      
                                       USA                                                                                                                                                                                                                                                                              

  Chotel *et al*\                      Retrospective\                          33 synovial sarcoma                          12.3\            98 (2--364)‡†            NR                                                                                                                                                No association
  2008[@R54]                           1985--2006\                                                                          (3-16)‡†                                                                                                                                                                                    
                                       UK                                                                                                                                                                                                                                                                               

  Nandra *et al*\                      Retrospective\                          2277 STS                                     57\*             NR                       No association                                                                                                                                    1-year mortality (13%), survivors longer total interval (20 vs 26 weeks)
  2015[@R27]                           1985--2010\                                                                                                                                                                                                                                                                      
                                       UK                                                                                                                                                                                                                                                                               

  Smolle *et al*\                      Retrospective\                          248 synovial sarcomas                        37‡              52\*                     NR                                                                                                                                                No association (\<1 year versus \>1 year)
  2019[@R68]                           1982--2014\                                                                                                                                                                                                                                                                      
                                       UK                                                                                                                                                                                                                                                                               

  \<16§                                49.8\*                                                                                                                                                                                                                                                                           

  ≥16§                                 52\*                                                                                                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Median.

†Range within brackets.

‡Mean.

§Included group of patients.

STS, soft tissue sarcomas.

Five of these studies observed no effect on survival.[@R54] One study (n=2 277) reported that patients with STS treated between 1985 and 2010 with a longer total interval (26 vs 20 weeks) had a significantly improved survival rate, even when stratified by disease stage.[@R27] This pattern was consistent for all histological subtypes apart from rhabdomyosarcoma where survival was significantly better with a short total interval (n=34, 16 vs 52 weeks total interval). Furthermore, patients undergoing unplanned resections prior to specialist referral had a lower 1-year mortality rate than patients referred directly. These patients tended to have small, superficial, low-grade tumours, which are associated with a better prognosis.

Three studies reported that patients with a shorter total interval had improved overall survival rates.[@R43] Ferrari *et al* analysed the risk of death for 575 children at different time intervals and found worse survival with increased diagnostic interval and with diagnostic intervals \<1 month vs 1--3 months (HR 1.4 (95% CI 0.7 to 2.6)) and \<1 month vs \>12 months (HR 3.6 (95% CI 1.7 to 8.0)), respectively.[@R67] Bandyopadhyay *et al* (n=391) reported that the odds of death increased by 46% for every doubling of the diagnostic interval.[@R43]

No study has investigated the influence of the length of the total interval on patient-reported outcomes.

Discussion {#s4}
==========

To the best of our knowledge, there is no published systematic review on the sarcoma total diagnostic interval. Analysis of the length of the total interval is complex, as it is influenced by many different factors. In sarcomas, assessment of the total interval is further challenged by the heterogeneity of the disease, the rarity of the group and the presence of 70+ subtypes.

Focusing on the patient interval, it might be anticipated that patients who consult a doctor early have a reason for doing so (eg, worrying, severe symptoms or evidence of rapid progression), which would result in a quicker referral for investigation and a shorter diagnostic interval[@R16] and vice versa.[@R12] However, some aspecific symptoms such as pain have given contradictory results.[@R22]

Both patient and doctor intervals might be influenced by the biological behaviour of the sarcoma. The usually indolent chondrosarcomas had a longer total interval than the more aggressive osteo and Ewing sarcomas,[@R12] and non-rhabdomyosarcoma STS had a longer total interval than rhabdomyosarcomas or soft tissue ESFT.[@R67]

Furthermore, tumour location influences the length of the total interval, with atypical tumour presentations increasing the difficulties in diagnosis and prolonging the diagnostic interval.

There are two main findings from studies of the primary and secondary care intervals. First, if at initial presentation the assessing clinician is falsely reassured or makes an incorrect diagnosis, the diagnostic interval is severely prolonged.[@R47] Second, patients undergoing an unplanned resection prior to referral to a specialist centre have a lower 1-year mortality rate than those referred directly to a specialist centre.[@R27] This finding may be due to selection bias, as patients undergoing unplanned resections have smaller, superficial and lower grade tumours, which are known factors associated with a better prognosis.

The influence of the length of the total interval on clinical outcomes remains unclear. It might be predicted that sarcomas with more aggressive behaviour have a shorter total interval and worse survival outcomes, while sarcomas with indolent behaviour have a longer total interval and improved survival. Alternatively, it may be expected that shorter total intervals lead to earlier treatment and better outcomes. For STS, we found conflicting results, which is not surprising with over 70 histological subtypes with different clinical behaviours. Most BS studies from our review not report an association between length of total interval and survival as well. Researchers have argued that this lack of an association, often referred to as the 'waiting-time paradox', may be due to the fact that the studies have not been able to adjust for the aggressiveness of the tumour.

To date, the influence of total interval on morbidity, HRQoL and other patient-reported outcomes has not been assessed. Based on the available literature in other malignancies, improving the total interval will likely influence the level of patient satisfaction, fear and morbidity. The importance of these outcomes is demonstrated by Mesko *et al* who studied factors most commonly causing litigation in sarcoma cases in the USA.[@R70] In 81% of cases, a delay in diagnosis was part of the complaint, a further 7% were about misdiagnosis and 11% about unnecessary amputation. Primary care doctors and orthopaedic specialists were most common defendants in delay in diagnosis cases.

In neither BS or STS did our review identify a clear cut-off point for appropriate versus inappropriate length of total interval or its components. Apart from the contradictory results in terms of influence of the length of the interval on survival, several other factors make it difficult to draw firm conclusions. First, the design of most studies was retrospective, increasing the chance of recall bias with regard to self-reported outcomes such as dates of first symptoms. Second, many studies included a small number of heterogeneous patients, which made them unsuitable for subtype analysis. Although we excluded case reports, we included case series because they reflect the sort of research that has been done in this area, and show how heterogeneous the population is. Third, the inclusion criteria of studies differed; some studies only considered those patients who reported a diagnostic delay, which made it impossible to compare this group to the entire sarcoma population. Furthermore, diagnostic delay was defined differently throughout the literature. One of the limitations of this review is that we had to work with these different definitions, which made comparisons difficult. We propose for future reports that the date of pathological diagnosis is used as the endpoint of the diagnostic interval. Furthermore, studies included in this review were conducted over the past 50 years. During this period, radiological and histological diagnostic techniques have evolved, treatment options have improved, and, in some countries, diagnostic pathways with referrals of suspected lumps to centralised sarcoma services have developed, which may have influenced our results.

Centralised sarcoma care may improve diagnostic pathways and there is an increasing number of (inter) national guidelines for the diagnosis and management of sarcomas.[@R71] Centralising care at sarcoma centres with a multidisciplinary team improves the diagnostic interval because patients (1) do not lose time at local hospitals, (2) receive appropriate imaging for tumour staging and (3) get a higher rate of correct preoperative pathologic diagnosis.[@R10] Improvement of these factors decrease tumour size and stage at diagnosis, resulting in an increase of the quality of surgery and improvement of survival outcomes in several of these studies.[@R60] Best practices of different countries could be integrated to develop the optimal diagnostic pathway. In order for such guidelines to be successfully implemented, one needs strong political support with continuous attention to raise awareness and optimise the system by following a quality and control cycle.[@R60]

Conclusion {#s5}
==========

This review confirms the complexity of the total interval to sarcoma diagnosis. Published studies give contradictory results in terms of determinants for a long total interval as well as its influence on outcomes. The impact of a long interval on HRQoL has not been studied. To present a clinically relevant cut-off point that discriminates between a short or long interval is thus impossible. Such a cut-off point, which can differ between histological subtypes, is necessary to make guidelines more evidence based, help to guide patients and support the sarcoma diagnostic process. Furthermore, to improve care we need to understand the impact of the total interval on HRQoL of patients diagnosed with a sarcoma. Future research should include relevant outcomes for patients, as well as focus on areas where a change in management could make a difference, such as in increased public awareness, education of primary and secondary healthcare providers and improved access to specialist centres.
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